Gabriele Pollara

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/369379/publications.pdf

Version: 2024-02-01

42 papers	1,216 citations	394421 19 h-index	395702 33 g-index
50 all docs	50 docs citations	50 times ranked	1939 citing authors

#	Article	IF	Citations
1	Rapid synchronous type 1 IFN and virus-specific TÂcell responses characterize first wave non-severe SARS-CoV-2 infections. Cell Reports Medicine, 2022, 3, 100557.	6.5	36
2	Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. Journal of Antimicrobial Chemotherapy, 2021, 76, 1323-1331.	3.0	35
3	Transcriptional response modules characterize IL-1Î² and IL-6 activity in COVID-19. IScience, 2021, 24, 101896.	4.1	28
4	Persistent TÂCell Repertoire Perturbation and TÂCell Activation in HIV After Long Term Treatment. Frontiers in Immunology, 2021, 12, 634489.	4.8	15
5	Tocilizumab in Treatment for Patients With COVID-19. JAMA Internal Medicine, 2021, 181, 1019.	5.1	0
6	Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease. Science Translational Medicine, 2021, 13, .	12.4	27
7	Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19. Journal of Infection, 2021, 83, 607-635.	3.3	3
8	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe, The, 2021, 2, e508-e517.	7.3	52
9	Vitamin D3 replacement enhances antigen-specific immunity in older adults. Immunotherapy Advances, 2021, 1, .	3.0	18
10	C-reactive protein-guided use of procalcitonin in COVID-19. JAC-Antimicrobial Resistance, 2021, 3, dlab180.	2.1	9
11	Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy. Clinical Infectious Diseases, 2020, 71, 207-210.	5.8	18
12	Routine Outpatient Parenteral Antimicrobial Therapy Clinic Review Minimizes Inpatient Readmission. Clinical Infectious Diseases, 2020, 71, 2771-2773.	5.8	0
13	Clinical outcomes of teicoplanin use in the OPAT setting. International Journal of Antimicrobial Agents, 2020, 55, 105888.	2.5	8
14	Keep calm and carry on learning: using Microsoft Teams to deliver a medical education programme during the COVID-19 pandemic. Future Healthcare Journal, 2020, 7, e67-e70.	1.4	56
15	Antiviral treatment for COVID-19: the evidence supporting remdesivir. Clinical Medicine, 2020, 20, e215-e217.	1.9	4
16	Assessing the Impact of Sample Heterogeneity on Transcriptome Analysis of Human Diseases Using MDP Webtool. Frontiers in Genetics, 2019, 10, 971.	2.3	17
17	Shortening duration of ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections: A retrospective study. PLoS ONE, 2019, 14, e0223130.	2.5	2
18	Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 370-380.	5.6	27

#	Article	IF	Citations
19	Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy. Journal of Antimicrobial Chemotherapy, 2019, 74, 787-790.	3.0	40
20	Tissue Metabolic Changes Drive Cytokine Responses to Mycobacterium tuberculosis. Journal of Infectious Diseases, 2018, 218, 165-170.	4.0	11
21	Time Efficiency Assessment of Antimicrobial Stewardship Strategies. Clinical Infectious Diseases, 2017, 64, 1463-1464.	5.8	5
22	Tumor Necrosis Factor (TNF) Bioactivity at the Site of an Acute Cell-Mediated Immune Response Is Preserved in Rheumatoid Arthritis Patients Responding to Anti-TNF Therapy. Frontiers in Immunology, 2017, 8, 932.	4.8	25
23	Validation of Immune Cell Modules in Multicellular Transcriptomic Data. PLoS ONE, 2017, 12, e0169271.	2.5	27
24	Modular deconvolution of tissue transcriptomes: pitfalls and solutions. Lancet, The, 2016, 387, S83.	13.7	0
25	Attitudes and Behaviours to Antimicrobial Prescribing following Introduction of a Smartphone App. PLoS ONE, 2016, 11, e0154202.	2.5	34
26	In Vivo Molecular Dissection of the Effects of HIV-1 in Active Tuberculosis. PLoS Pathogens, 2016, 12, e1005469.	4.7	46
27	eICID: An electronic Clinical Infection Database to support integrated clinical services and research in infectious diseases. Journal of Infection, 2015, 71, 402-405.	3.3	8
28	Citrobacter koseri meningitis: Another freediving risk?. Journal of Infection, 2011, 62, 101-103.	3.3	4
29	Impact of UK academic foundation programmes on aspirations to pursue a career in academia. Medical Education, 2010, 44, 996-1005.	2.1	27
30	Glycoprotein-Dependent and TLR2-Independent Innate Immune Recognition of Herpes Simplex Virus-1 by Dendritic Cells. Journal of Immunology, 2008, 180, 7525-7536.	0.8	53
31	Expression and function of mixed lineage kinases in dendritic cells. International Immunology, 2007, 19, 923-933.	4.0	15
32	Understanding HSV-1 entry glycoproteins. Reviews in Medical Virology, 2007, 17, 205-215.	8.3	98
33	Autocrine Type I Interferon Amplifies Dendritic Cell Responses to Lipopolysaccharide via the Nuclear Factor-kappaB/p38 Pathways. Scandinavian Journal of Immunology, 2006, 63, 151-154.	2.7	12
34	Dendritic cells in viral pathogenesis: protective or defective?. International Journal of Experimental Pathology, 2005, 86, 187-204.	1.3	51
35	JNK activation limits dendritic cell maturation in response to reactive oxygen species by the induction of apoptosis. Free Radical Biology and Medicine, 2005, 38, 1637-1652.	2.9	39
36	The use of targeted microbeads for quantitative analysis of the phagocytic properties of human monocyte-derived dendritic cells. Journal of Immunological Methods, 2005, 297, 27-38.	1.4	6

#	Article	IF	Citations
37	LIGHTing up dendritic cell activation: Immune regulation and viral exploitation. Journal of Cellular Physiology, 2005, 205, 161-162.	4.1	16
38	Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence?. Lancet Infectious Diseases, The, 2005, 5, 296-304.	9.1	75
39	Herpes Simplex Virus Type-1-Induced Activation of Myeloid Dendritic Cells: The Roles of Virus Cell Interaction and Paracrine Type I IFN Secretion. Journal of Immunology, 2004, 173, 4108-4119.	0.8	79
40	The host response to herpes simplex virus infection. Current Opinion in Infectious Diseases, 2004, 17, 199-203.	3.1	38
41	Herpes Simplex Virus Infection of Dendritic Cells: Balance among Activation, Inhibition, and Immunity. Journal of Infectious Diseases, 2003, 187, 165-178.	4.0	113
42	The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Research, 2003, 63, 5143-50.	0.9	20